Inflammatory Myositis Epidemiology Forecast 2026-2035

Inflammatory myositis, particularly idiopathic inflammatory myopathies, is a rare autoimmune disorder affecting skeletal muscles. According to Aleksandra Markowska et al., 2025, the global incidence ranges from 0.2 to 2 per 100,000 person-years, with prevalence between 2 and 25 per 100,000 individuals. According to inflammatory myositis epidemiology forecast, diagnosed cases are expected to rise steadily worldwide.

Inflammatory Myositis Epidemiology Forecast Report Coverage

The analyst's “Inflammatory Myositis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of inflammatory myositis. It projects the future incidence and prevalence rates of inflammatory myositis cases across various populations. The study covers age, gender, and type as major determinants of the inflammatory myositis population. The report highlights patterns in the prevalence of inflammatory myositis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of inflammatory myositis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Inflammatory Myositis Understanding: Disease Overview

Inflammatory myositis refers to a group of rare autoimmune disorders characterized by chronic inflammation of skeletal muscles, leading to progressive weakness and fatigue. It occurs when the immune system mistakenly attacks healthy muscle fibers, causing muscle damage and impaired function. The condition may also involve the skin, lungs, and other organs. Major types include polymyositis, dermatomyositis, inclusion body myositis, and juvenile myositis. Symptoms vary but commonly include muscle weakness, difficulty swallowing, and fatigue.

Inflammatory Myositis Epidemiology Perspective

The inflammatory myositis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the inflammatory myositis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for inflammatory myositis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to PM&R KnowledgeNow, global prevalence of idiopathic inflammatory myopathies ranges from 2.9 to 34 per 100,000 population, with incidence varying widely between 11 and 660 cases per 1,000,000 person-years across regions.
• As per Aneta A. Urbańczyk (2025), overall prevalence is estimated at 2-25 per 100,000 individuals, with polymyositis affecting approximately 1 in 100,000 people, highlighting the rarity and variability in epidemiological reporting across different populations.
• According to PM&R KnowledgeNow, incidence increases with age, peaking around 50 years, while juvenile-onset cases show distinct patterns, including higher risks of cardiovascular and cerebrovascular comorbidities among ethnic minority populations.
• As per Samar Tharwat et al. (2026), inflammatory myositis demonstrates a strong female predominance, with 83.8% of patients being women, consistent with broader findings that dermatomyositis and polymyositis occur more frequently in females.
• According to Marwah et al. (2024), mortality in inflammatory myositis is largely driven by interstitial lung disease, contributing to nearly 80% of deaths, while improved early diagnosis and treatment have gradually reduced overall mortality rates.

Country-wise Inflammatory Myositis Epidemiology

The inflammatory myositis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the studied regions, inflammatory myositis demonstrates a low but variable epidemiological burden with notable geographic differences. In the United States, incidence ranges from 0.1-1 per 100,000 person-years and prevalence from 1.4-5.8 per 100,000, as per Kristina Terrani et al., 2024. Data from the United Kingdom, Germany, France, Spain, and Italy suggest similarly rare prevalence, generally within 2-10 per 100,000 individuals, according to regional registry analyses. In Japan and India, epidemiological insights remain limited; however, as per Samuel Katsuyuki Shinjo et al., 2023, India contributed 13.1% of global IIM cohort data, indicating growing recognition, thereby reflecting evolving epidemiological understanding across these regions.

Inflammatory Myositis: Treatment Overview

Treatment of inflammatory myositis focuses on reducing inflammation, improving muscle strength, and preventing complications. First-line therapy typically involves corticosteroids such as prednisone, often combined with immunosuppressive agents like methotrexate or azathioprine to enhance efficacy and reduce steroid dependence. In refractory cases, biologic therapies and intravenous immunoglobulin may be used. Physical therapy plays a crucial role in maintaining mobility and muscle strength. Early diagnosis and a multidisciplinary approach are essential to optimize outcomes and manage systemic involvement.

Key Questions Answered

• What are the key findings of inflammatory myositis epidemiology in the 8 major markets?
• What will be the total number of patients with inflammatory myositis across the 8 major markets during the forecast period?
• What was the country-wise inflammatory myositis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of inflammatory myositis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of inflammatory myositis during the forecast period of 2026-2035?
• What are the currently available treatments for inflammatory myositis?
• What are the disease risks, signs, symptoms, and unmet needs of inflammatory myositis?

Scope of the Inflammatory Myositis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of inflammatory myositis based on several factors.
• Inflammatory Myositis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The inflammatory myositis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.